natgillin/translations-raw huggingface dataset:
Evidens for klinisk virkning af raltegravir blev baseret på analyserne af 96-ugers data fra to randomiserede, dobbeltblindede, placebokontrollerede studier (BENCHMRK 1 og BENCHMRK 2, Protokol 018 og 019) hos antiretrovirale behandlingserfarne hiv-1 inficerede voksne patienter, analysen fra 240-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (STARTMRK, Protokol 021) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter og analysen af 96-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (ONCEMRK, Protokol 292) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter. 
The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients, the analysis of 240-week data from randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients and the analysis of 96-week data from randomised, double-blind, active-control trial (ONCEMRK, Protocol 292) in antiretroviral treatment-naïve HIV-1 infected adult patients.
Raltegravir to gange dagligt er blevet undersøgt hos 126 antiretrovirale behandlingserfarne hiv-1inficerede børn og unge i alderen 2 til 18 år i kombination med andre antiretrovirale lægemidler i IMPAACT P1066 (se pkt. 
Raltegravir twice daily has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 to 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
• Gener i brystet, kuldegysninger, hævelser i ansigtet, anspændthed, generel utilpashed, hævet hals, hævede hænder, ankler eller fødder, smerter 
• chest discomfort; chills; swelling of face; feeling jittery; generally feeling unwell; neck mass; swelling of hands, ankles or feet; pain
Evidens for klinisk effekt af raltegravir blev baseret på analyserne af 96-ugers data fra to randomiserede, dobbeltblindede, placebokontrollerede studier (BENCHMRK 1 og BENCHMRK 2, Protokol 018 og 019) hos antiretrovirale behandlingserfarne hiv-1 inficerede voksne patienter samt analysen fra 240-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (STARTMRK, Protokol 021) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter. 
The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients and the analysis of 240-week data from a randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients.
* Den vægtbaserede doseringsanbefaling for tyggetabletten og den orale suspension i 10 ml vand er baseret på ca. 6 mg/kg/dosis to gange dagligt (se pkt. 
1.5 x 100 mg twice daily *The weight-based dosing recommendation for the chewable tablet, and oral suspension in 10mL of water is based on approximately 6 mg/kg/dose twice daily (see section 5.2).
Behandlingserfarne voksne patienter (400 mg to gange dagligt) BENCHMRK 1 og BENCHMRK 2 (randomiserede, dobbeltblindede, placebokontrollerede multicenterstudier) vurderede sikkerheden og den antiretrovirale aktivitet af raltegravir 400 mg to gange dagligt versus placebo i en kombination med OBT hos hiv-inficerede patienter, i alderen 16 år og ældre, der har dokumenteret resistens over for mindst ét lægemiddel i hver af de 3 klasser (NRTIere, NNRTIere, PIere) af antiretroviral terapi. 
Treatment-experienced adult patients (400 mg twice daily) BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimised background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Dosisjustering af raltegravir eller midazolam er ikke nødvendig. 
No dosage adjustment required for raltegravir or midazolam.
Resultater af uge 48- og 96-analyser 
Results 48-week and 96-week analyses
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Tyggetablet 100 mg 
Chewable tablet 100 mg
Dosisjustering af raltegravir eller etravirin er ikke nødvendig. 
No dose adjustment required for raltegravir or etravirine.
Samtidig administration af raltegravir og aluminiumog/eller magnesiumholdige antacida frarådes (se pkt. 
Co-administration of raltegravir with aluminium and/or magnesium antacids is not recommended (see section 4.5).
STARTMRK (randomiseret, dobbeltblindet, aktivt kontrolleret multicenterstudie) vurderede sikkerhed og antiretroviral aktivitet af raltegravir 400 mg to gange dagligt versus efavirenz 600 mg ved sengetid i en kombination med emtricitabin (+) tenofovirdisoproxilfumarat hos behandlingsnaive hiv-inficerede patienter med hiv-RNA >5.000 kopier/ml. 
STARTMRK (multi-centre, randomised, double-blind, active-control trial) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-naïve HIV-infected patients with HIV RNA > 5,000 copies/mL.
2 x 100 mg to gange dagligt 
2 x 100 mg twice daily
Sådan skal du tage Isentress 
How to take Isentress
Tyggetabletten med appelsin-banansmag er rund, lysegul, mærket med MSD-virksomhedslogo og "473" på den anden side. 
The orange-banana flavoured chewable tablet is round and pale yellow, marked with the MSD corporate logo on one side and “473” on the other side.
ISENTRESS 25 mg tyggetabletter ISENTRESS 100 mg tyggetabletter. 
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets
Karton til 400 mg filmovertrukne tabletter 
Carton for 400 mg film-coated tablets
), median [interval] CD4-procent, median [interval] Hiv-1 RNA >100.000 kopier/ml CDC hiv-kategori B eller C Tidligere antiretroviral behandling iht. 
), median [range] CD4 percent, median [range] HIV-1 RNA >100,000 copies/mL CDC HIV category B or C Prior ART Use by Class NNRTI NRTI PI
Bivirkningen rabdomyolyse blev rapporteret med hyppigheden ikke almindelig i forbindelse med brug af raltegravir 400 mg to gange dagligt efter markedsføring. 
Rhabdomyolysis was an uncommonly reported serious adverse reaction in post-marketing use of raltegravir 400 mg twice daily.
Skift til raltegravir (400 mg to gange dagligt) 
Switch to raltegravir (400 mg twice daily)
Flaske til ISENTRESS 600 mg filmovertrukne tabletter 
Bottle for ISENTRESS 600 mg film-coated tablets
Ved den prognostiske analyse blev virologisk svigt analyseret som "carry forward" for procent med henholdsvis < 400 og ≤ 50 kopier/ml. 
For analysis by prognostic factors, virologic failures were carried forward for percent < 400 and 50 copies/mL.
Nukleoside/tide reverse transkriptasehæmmere tenofovirdisoproxilfumarat (raltegravir 400 mg to gange dagligt) 
Nucleoside/tide reverse transcriptase inhibitors tenofovir disoproxil fumarate (raltegravir 400 mg Twice Daily)
Antacida med aluminium og magnesium nedsætter raltegravirs plasmakoncentration. 
Aluminium and magnesium containing antacids reduce raltegravir plasma levels.
Den filmovertrukne 600 mg tablet er oval, gul, med MSD-virksomhedslogo og "242" præget på den ene side og uden prægning på den anden side. 
What Isentress looks like and contents of the pack The 600 mg film-coated tablet is oval-shaped, yellow, marked with MSD corporate logo and "242" on one side and plain on the other side.
Administration af raltegravir sammen med aluminiumog/eller magnesiumholdige antacida frarådes. 
Co-administration of raltegravir with aluminium and/or magnesium containing antacids is not recommended.
• Herpesinfektion, fx helvedesild 
• herpes infections including shingles
Enkeltdosisfoliepose til ISENTRESS 100 mg granulat til oral suspension - foliepose 
Unit dose sachet for ISENTRESS 100 mg granules for oral suspension - foil sachet
Karton til 600 mg filmovertrukne tabletter 
Carton for 600 mg film-coated tablets
raltegravir AUC  67% raltegravir C24t  26% raltegravir Cmax  16% 
raltegravir AUC  67% raltegravir C24hr  26% raltegravir Cmax  16%
Lys orange, oval tyggetablet med delekærv på begge sider, præget med MSD-virksomhedslogo og "477" på den ene side og ingen prægning på den anden side. 
Pale orange coloured, oval shaped, chewable tablet scored on both sides with the MSD corporate logo and "477" on one side and without inscription on the other side.
25 mg tyggetabletter: Hver tyggetablet indeholder 25 mg raltegravir (som kalium). 
25 mg chewable tablets: Each chewable tablet contains 25 mg of raltegravir (as potassium).
60 tyggetabletter 
60 chewable tablets
Akne, alopeci, akneiform dermatitis, tør hud, erytem, tab af fedt i ansigtet, hyperhidrose, lipoatrofi, erhvervet lipodystrofi, lipohypertrofi, nattesved, prurigo, pruritus, generaliseret pruritus, makuløst udslæt, makulopapuløst udslæt, kløende udslæt, hudlæsioner, urticaria, xeroderma, StevensJohnsons syndrom, lægemiddeludslæt med eosinofili og systemiske symptomer (DRESS) 
Uncommon acne, alopecia, dermatitis acneiforme, dry skin, erythema, facial wasting, hyperhidrosis, lipoatrophy, lipodystrophy acquired, lipohypertrophy, night sweats, prurigo, pruritus, pruritus generalised, rash macular, rash maculopapular, rash pruritic, skin lesion, urticaria, xeroderma, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)
Procent hiv-RNA < 50 kopier/ml (95% CI) Alle patienter 
Percent HIV-RNA < 50 copies/mL (95 % CI) All patients
Norelgestromin (raltegravir 400 mg to gange dagligt) 
Norelgestromin (raltegravir 400 mg Twice Daily)
Isentress 25 mg tyggetabletter Isentress 100 mg tyggetabletter raltegravir 
Isentress 25 mg chewable tablets Isentress 100 mg chewable tablets raltegravir
100 mg tyggetabletter: Hver tyggetablet indeholder 100 mg raltegravir (som kalium). 
100 mg chewable tablets: Each chewable tablet contains 100 mg of raltegravir (as potassium).
ISENTRESS 100 mg granulat til oral suspension 
ISENTRESS 100 mg granules for oral suspension
raltegravir AUC  72% raltegravir C24t  48% raltegravir Cmax  74% 
raltegravir AUC  72% raltegravir C24 hr  48% raltegravir Cmax  74%
Raltegravir 600 mg (1.200 mg en gang dagligt) (N = 531) 
Raltegravir 600 mg (1,200 mg once daily)
Administration af atazanavir sammen med raltegravir 1.200 mg en gang dagligt øgede raltegravirs plasmakoncentration signifikant. 
Co-administration of atazanavir with raltegravir 1,200 mg once daily significantly increased plasma levels of raltegravir; therefore, co-administration of raltegravir 1,200 mg once daily and atazanavir is not recommended.
1,5 x 100 mg † to gange dagligt 
1.5 x 100 mg † twice daily
OPIOIDANALGETIKA methadon (raltegravir 400 mg to gange dagligt) 
OPIOID ANALGESICS methadone (raltegravir 400 mg Twice Daily)
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om. 
You should check with your doctor, pharmacist or nurse if you are not sure.
Hvis du har taget for meget Isentress 
If you take more Isentress than you should
Flaske til ISENTRESS 400 mg - filmovertrukne tabletter 
Bottle for ISENTRESS 400 mg film-coated tablets
Alle patienter Karakteristika ved baseline Hiv-RNA > 100.000 kopier/ml ≤ 100.000 kopier/ml 
Baseline Characteristic HIV-RNA > 100,000 copies/mL
Ikke almindelig Nyresvigt, nefritis, nefrolitiasis, nykturi, nyrecyste, nedsat nyrefunktion, tubulo-interstitiel nefritis 
Renal and urinary disorders Uncommon renal failure, nephritis, nephrolithiasis, nocturia, renal cyst, renal impairment, tubulointerstitial nephritis
Tabel 5 viser de farmakokinetiske parametre for 400 mg tabletten, tyggetabletten og granulatet til oral suspension ud fra kropsvægt. 
Table 5 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
antacidum med calciumcarbonat (raltegravir 400 mg to gange dagligt) 
calcium carbonate antacid (raltegravir 400 mg Twice Daily)
Antal tyggetabletter 
Number of chewable tablets
12 timer efter raltegravir raltegravir AUC  14% raltegravir C24t  58% raltegravir Cmax  14% 
12 hours after raltegravir raltegravir AUC  14% raltegravir C24 hr  58% raltegravir Cmax  14%
etravirin AUC  10% etravirin C12t  17% etravirin Cmax  4% 
etravirine AUC  10 % etravirine C12hr  17 % etravirine Cmax  4 %
Ikke almindelig Erektil dysfunktion, gynækomasti, menopausesymptomer 
Uncommon erectile dysfunction, gynaecomastia, menopausal symptoms
ISENTRESS 100 mg granulat til oral suspension raltegravir 
Isentress 100 mg granules for oral suspension raltegravir
• Smerter i øverste del af maven, gener i endetarmen, forstoppelse, tør mund, halsbrand, synkesmerter, betændelse i bugspytkirtlen, sår eller ømhed i maven eller øvre del af mave-tarmkanalen, blødning ved endetarmen, mavegener, tandkødsbetændelse, hævet, rød, øm tunge 
• abdominal pain upper; rectal discomfort; constipation; dry mouth; heartburn; pain when swallowing; inflammation of the pancreas; ulcer or sore in stomach or upper intestine; bleeding at anus; stomach discomfort; inflammation of the gums; swollen, red sore tongue
antacidum med calciumcarbonat (raltegravir 1.200 mg enkeltdosis) 
Recommendations concerning co-administration calcium carbonate antacid (raltegravir 1,200 mg single dose)
- Hydroxypropylcellulose - Sucralose - Mannitol - Monoammoniumglycyrrhizinat - Sorbitol (E420) - Fructose - Banansmag - Sucrose - Crospovidon, type A - Magnesiumstearat - Hypromellose 2910/6cP - Macrogol/PEG 400 - Ethylcellulose 20 cP - Ammoniumhydroxid - Triglycerider, middelkædelængde - Oliesyre - Mikrokrystallinsk cellulose - Carmellosenatrium 
- Hydroxypropyl cellulose - Sucralose - Mannitol - Monoammonium glycyrrhizinate - Sorbitol (E420) - Fructose - Banana flavour - Sucrose - Crospovidone, Type A - Magnesium stearate - Hypromellose 2910/6cP - Macrogol/PEG 400 - Ethylcellulose 20 cP - Ammonium hydroxide - Medium chain triglycerides - Oleic acid - Microcrystalline cellulose - Carmellose sodium
Behandlingsdifferencen (raltegravir 1.200 mg en gang dagligt - raltegravir 400 mg to gange dagligt) var 0,5% med associeret 95% konfidensinterval (-4,2; 5,2), hvilket fastslog. 
The treatment difference (raltegravir 1,200 mg once daily-raltegravir 400 mg twice daily) was 0.5 % with an associated 95 % CI of (-4.2, 5.2) establishing that raltegravir 1,200 mg once daily is non-inferior to raltegravir 400 mg twice daily.
ISENTRESS 600 mg filmovertrukne tabletter 
ISENTRESS 600 mg film-coated tablets
Karton til 100 mg tyggetabletter 
Carton for 100 mg chewable tablets
Se produktresuméerne for 400 mg tabletten og tyggetabletten for yderligere oplysninger om dosering. 
Refer to the 400 mg and chewable tablet SmPCs for additional dosing information.
Behandlingsnaive voksne patienter (400 mg to gange dagligt) STARTMRK (randomiseret, dobbeltblindet, aktivt kontrolleret multicenterstudie) vurderede sikkerhed og antiretroviral aktivitet af raltegravir 400 mg to gange dagligt versus efavirenz 600 mg ved sengetid i en kombination med emtricitabin (+) tenofovirdisoproxilfumarat hos behandlingsnaive hiv-inficerede patienter med hiv-RNA >5.000 kopier/ml. 
Treatment-naïve adult patients (400 mg twice daily) STARTMRK (multi-centre, randomised, double-blind, active-control trial) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-naïve HIV-infected patients with HIV RNA > 5,000 copies/mL.
300 mg to gange dagligt 
300 mg twice daily
raltegravir AUC  14% raltegravir C24t  6% raltegravir Cmax  9% 
raltegravir AUC  14% raltegravir C24hr  6% raltegravir Cmax  9%
etravirin (raltegravir 400 mg to gange dagligt) 
etravirine (raltegravir 400 mg Twice Daily)
Karton til 25 mg tyggetabletter 
Carton for the 25 mg chewable tablets
Hvis samtidig administration med rifampicin er uundgåelig, kan en dobbelt dosis raltegravir overvejes. 
If co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered (see section 4.4).
• Leverbetændelse 
• stomach inflammation
Tabel 8 viser de farmakokinetiske parametre for 400 mg tabletten, tyggetabletten og granulatet til oral suspension ud fra kropsvægt. 
Table 8 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
Øvrige indholdsstoffer: hydroxypropylcellulose, sucralose, mannitol, monoammoniumglycyrrhizinat, sorbitol (E420), fructose, banansmag, sucrose, crospovidon type A, magnesiumstearat, ethylcellulose 20 cP, ammoniumhydroxid, triglycerider af middelkædelængde, oliesyre, hypromellose 2910/6cP, macrogol/PEG 400, mikrokrystallisk cellulose og carmellosenatrium. 
The other ingredients are: hydroxypropyl cellulose, sucralose, mannitol, monoammonium glycyrrhizinate, sorbitol (E420), fructose, banana flavour, sucrose, crospovidone Type A, magnesium stearate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP, macrogol/PEG 400, microcrystalline cellulose and carmellose sodium.
Dosisjustering af raltegravir (400 mg to gange dagligt og 1.200 mg en gang dagligt) eller tenofovirdisoproxilfumarat er ikke nødvendig. 
No dose adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or tenofovir disoproxil fumarate.
Den filmovertrukne tablet er oval, lyserød, mærket "227" på den ene side. 
What Isentress looks like and contents of the pack The film-coated tablet is oval-shaped, pink, marked with "227" on one side.
raltegravir AUC ↑ 37% raltegravir C12t ↑ 24% raltegravir Cmax ↑ 51% 
raltegravir AUC ↑ 37 % raltegravir C12 hr ↑ 24 % raltegravir Cmax ↑ 51 %
Hver tablet indeholder 25 mg raltegravir (som kalium). 
Each tablet contains 25 mg of raltegravir (as potassium).
Procent hiv-RNA < 40 kopier/ml (95 % CI) 
Percent HIV-RNA < 40 copies/mL (95 % CI)
Tyggetabletter 100 mg - Hydroxypropylcellulose - Sucralose - Natriumsaccharin - Dinatriumcitrat - Mannitol - Monoammoniumglycyrrhizinat - Sorbitol (E420) - Fructose - Banansmag - Appelsinsmag - Smagsmaskering - Aspartam (E951) - Crospovidon, type A - Natriumstearylfumarat - Magnesiumstearat - Hypromellose 2910/6cP - Macrogol/PEG 400 - Ethylcellulose 20 cP - Ammoniumhydroxid - Triglycerider, middelkædelængde - Oliesyre - Rød jernoxid - Gul jernoxid 
Chewable tablet 100 mg - Hydroxypropyl cellulose - Sucralose - Saccharin sodium - Sodium citrate dihydrate - Mannitol - Monoammonium glycyrrhizinate - Sorbitol (E420) - Fructose - Banana flavour - Orange flavour - Masking flavour - Aspartame (E951) - Crospovidone, Type A - Sodium stearyl fumarate- Magnesium stearate - Hypromellose 2910/6cP - Macrogol/PEG 400 - Ethylcellulose 20 cP - Ammonium hydroxide - Medium chain triglycerides - Oleic acid - Red iron oxide - Yellow iron oxide
Tabel 6 viser de farmakokinetiske parametre for 400 mg tabletten , tyggetabletten og granulatet til oral suspension ud fra kropsvægt. 
Table 6 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
UGT1A1-hæmmere 
Inhibitors of UGT1A1
famotidin (raltegravir 400 mg to gange dagligt) 
famotidine (raltegravir 400 mg Twice Daily)
ISENTRESS 25 mg tyggetabletter raltegravir 
ISENTRESS 25 mg chewable tablets raltegravir
Resultaterne fra STARTMRK ved uge 48 og uge 240 for patienter på den anbefalede dosis raltegravir på 400 mg to gange dagligt ses i tabel 5. 
Week 48 and Week 240 outcomes for patients on the recommended dose of raltegravir 400 mg twice daily from STARTMRK are shown in Table 5.
Holdbare resultater (uge 48 og uge 96) for patienter, der fik den anbefalede dosis raltegravir 400 mg to gange dagligt, fra de poolede studier BENCHMRK 1 og BENCHMRK 2, fremgår af tabel 4. 
Durable outcomes (Week 48 and Week 96) for patients on the recommended dose raltegravir 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 4.
Følgende kan være nogle af de mange risikofaktorer, der findes for at udvikle denne sygdom: Varigheden af den antiretrovirale kombinationsbehandling, brug af kortikosteroider, alkoholforbrug, dannelsen af antistoffer er alvorligt hæmmet (immunsuppression), højt BMI. 
The length of combination anti-retroviral therapy, corticosteroid use, alcohol consumption, severe reduction of the activity of the immune system, higher body mass index, among others, may be some of the many risk factors for developing this disease.
opkastning, fordøjelsesproblemer, opstød 
vomiting; indigestion; belching
Hver filmovertrukken tablet indeholder 600 mg raltegravir (som kalium). 
Each film-coated tablet contains 600 mg of raltegravir (as potassium).
Opbevaring af Isentress 
How to store Isentress
Procent hiv-RNA < 50 kopier/ml (95% CI) 
Percent HIV-RNA < 50 copies/mL (95 % CI)
Dosisjustering af raltegravir er ikke nødvendig. 
No dose adjustment required for raltegravir.
raltegravir AUC  37% raltegravir C12t  28% raltegravir Cmax  33% 
raltegravir AUC  37 % raltegravir C12hr  28 % raltegravir Cmax  33 %
raltegravir AUC 37% raltegravir C12t 28% raltegravir Cmax 33% 
raltegravir AUC  37% raltegravir C12hr  28% raltegravir Cmax  33%
ISENTRESS filmovertrukne tabletter indeholder lactose og bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af arvelig lactasemangel (Lapp Lactase deficiency) eller glucose/galactose malabsorption. 
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
De øvrige indholdsstoffer er: hydroxypropylcellulose, sucralose, natriumsaccharin, dinatriumcitrat, mannitol, rød jernoxid, gul jernoxid, monoammoniumglycyrrhizinat, sorbitol (E420), fructose, naturlige og kunstige smagsvarianter (appelsin, banan og smagsmaskering), aspartam (E951), crospovidon type A, magnesiumstearat, natriumstearylfumarat, ethylcellulose 20 cP, ammoniumhydroxid, triglycerider af middelkædelængde, oliesyre, hypromellose 2910/6cP, og macrogol/PEG 400. 
The other ingredients are: hydroxypropyl cellulose, sucralose, saccharin sodium , sodium citrate dihydrate, mannitol, red iron oxide, yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E420), fructose, natural and artificial flavours (orange, banana, and masking), aspartame (E951), crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
raltegravir AUC 41% raltegravir C12t 77% raltegravir Cmax 24% 
raltegravir AUC  41% raltegravir C12hr  77% raltegravir Cmax  24%
Hver filmovertrukken tablet indeholder 400 mg raltegravir (som kalium). 
Each film-coated tablet contains 400 mg of raltegravir (as potassium).
Autoimmune lidelser (såsom Graves' sygdom og autoimmun hepatitis) er også rapporteret at forekomme i forbindelse med immunreaktivering. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation: however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.